A UK-based private diagnostics company has achieved an annualized revenue of £342,000 in 2026, maintaining a 44% adjusted EBITDA margin. This growth was accomplished without external investment, focusing on offering over 1,300 blood test types, which is among the broadest selections in the UK. The business collaborates with a US laboratory for discounted lab services in the UK. It creates customized blood test profiles per client and boasts a network of over 20 phlebotomists across major UK cities. Their AI health report platform, currently in MVP form, generates comprehensive personalized reports with supplement advice and other wellness recommendations. Revenue is primarily generated through direct consumer bookings, business partnerships, and medical product resale. Operations are maintained through a remote team, with substantial revenue growth achieved via organic SEO and modest Google Ads spending. In 2025, the company generated £238,494 in revenue, with a net profit of £48,771 and an adjusted EBITDA of £99,472, marking a 65% compound annual growth over two years. The current year's revenue is projected to exceed £342,000, with an SDE of over £169,000. A 3x TTM SDE valuation prices the business at £385,000. Operationally, it utilizes a mobile, asset-light model without premises costs, benefitting from negotiated laboratory fee discounts. Key growth opportunities include increased digital advertising, social media engagement, and expanding its phlebotomist network. The business is ready for significant scale and expansion with its established infrastructure and strategic partnerships, including a ready-to-launch international revenue stream in Spain.